Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

SPECT/CT signals diabetic bone disease

Hybrid molecular imaging can lead to diagnosis of osteomyelitis in diabetic patients via bedside bone puncture without the need for surgical or image-guided biopsy, according to a study published online in Diabetes Care in March.

Imaging Market: Molecular, Nanoscale, Atomic, Optical, Thermal and Infrared Imaging Industry Analysis in New Research Reports at RnRMarketResearch.com

"Global Markets and Technologies for Molecular, Nanoscale and Atomic Imaging", "Global Thermal Imaging Market 2012-2016", "Global Infrared Imaging Market 2012-2016" and "Optical Imaging Market (2013-2018)" reports are now available with RnR Market Research

CMS proposes to cover PET for most cancers, prostate excluded

The Centers for Medicare & Medicaid Services (CMS) released a proposed decision memo that outlined its suggestion to cover PET imaging for most solid tumors. CMS noted that PET monitoring of Medicare beneficiaries with prostate cancer is not reasonable and necessary.

Future looks bright for thyroid cancer molecular imaging, treatments

A number of research breakthroughs in molecular imaging and molecular-targeted treatments of thyroid cancer are showing signs of expansion into the clinic, according to a review in the March issue of The Lancet.

Amyloid tracer shows diagnostic promise for Alzheimer’s disease

The amyloid imaging agent F-18 florbetaben has been moving forward in clinical trials for the diagnosis of Alzheimer’s disease. The up and coming F-18 florbetaben is showing signs of similar effectiveness, according to research published in the May issue of The Journal of Nuclear Medicine that presented a dynamic model of amyloid imaging using the tracer.

SHINE MEDICAL TECHNOLOGIES FILES THE CONSTRUCTION PERMIT APPLICATION WITH NUCLEAR REGULATORY COMMISSION

SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in safe, clean, and affordable production of medical isotopes and cancer treatment elements, has submitted its Construction Permit application to the Nuclear Regulatory Commission (NRC). This submittal is the first formal step by SHINE in seeking an NRC permit to begin construction of its medical isotope facility in Janesville, Wisconsin.

AMIC teams with GSG International for Mo-99, Tech-99 distribution deal

Advanced Medical Isotope Corporation (AMIC) has entered into a strategic alliance with GSG International to collaborate in the joint development of technologies for the production of medical isotopes and the marketing and distribution of related isotopes, equipment and services.

Myocardial perfusion SPECT offers 5-year warranty

The short-term prognostic benefit of myocardial perfusion scintography (MPS) is well established, and the technique also delivers long-term value up to five years after initial imaging, according to a study in the Journal of Nuclear Cardiology.